Author

H. Kagechika

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:electrophysiology· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1 Organism:mouse· 1

Frequent Co-Authors

N. Kurebayashi· 3 shared S. Mori· 3 shared T. Murayama· 3 shared T. Sakurai· 3 shared R. Ishida· 2 shared T. Kobayashi· 2 shared A. Miura· 1 shared A. Uryas· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

N. Kurebayashi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Screening for novel RyR2 inhibitors by ER Ca2+ monitoring

M. Takenaka, M. Kodama, T. Murayama, M. Ishigami-Yuasa, S. Mori, R. Ishida, J. Suzuki, K. Kanemaru, M. Sugihara, M. Iino, A. Miura, H. Nishio, S. Morimoto, H. Kagechika, T. Sakurai, N. Kurebayashi

This study identifies three RyR2 inhibitors using an ER Ca2+ monitoring assay, showing they suppress arrhythmogenic Ca2+ waves without affecting normal Ca2+ transients.

bioRxiv · Aug 21, 2023 · PreprintPharmacology & Toxicology

Reconstituted depolarization-induced Ca2+ release platform for skeletal muscle disease mutation validation and drug discovery

T. Murayama, N. Kurebayashi, T. Numaga-Tomita, T. Kobayashi, S. Okazaki, K. Yamashiro, T. Nakada, S. Mori, R. Ishida, H. Kagechika, M. Yamada, T. Sakurai

The paper establishes a reconstituted DICR platform in HEK293 cells to validate skeletal muscle disease mutations and test drug candidates.

bioRxiv · Jun 29, 2022Physiology

A novel RyR1 inhibitor prevents and rescues sudden death in a mouse model of malignant hyperthermia and heat stroke

T. Yamazawa, T. Kobayashi, N. Kurebayashi, M. Konishi, S. Noguchi, T. Inoue, Y. U. Inoue, I. Nishino, S. Mori, H. Iinuma, N. Manaka, H. Kagechika, A. Uryas, J. Adams, J. R. Lopez, , T. Murayama

This study introduces a novel RyR1 inhibitor that prevents and rescues MH and heat stroke in mouse models, offering improved solubility and clearance compared to dantrolene.

bioRxiv · Jul 2, 2020 · PreprintPharmacology & Toxicology